Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

BUSINESS COMBINATIONS (Narrative) (Details)

v3.21.1
BUSINESS COMBINATIONS (Narrative) (Details)
€ in Thousands, $ in Thousands
1 Months Ended 12 Months Ended
Mar. 15, 2019
CAD ($)
Mar. 15, 2019
EUR (€)
Mar. 21, 2019
CAD ($)
Dec. 31, 2020
CAD ($)
Dec. 31, 2019
CAD ($)
Mar. 15, 2019
EUR (€)
Disclosure of detailed information about business combination [line items]            
Share based compensation of subsidiary       $ 59 $ 102  
Adjupharm GmbH ("Adjupharm") [Member]            
Disclosure of detailed information about business combination [line items]            
Percentage of issued and outstanding shares acquired 100.00%         100.00%
Cash transferred $ 1,400         € 924
Acquisition costs 104          
Amount to release security provided for bank loan and bank credit 1,026 € 680        
Amount deposited in escrow $ 1,090 € 720        
Adjupharm GmbH ("Adjupharm") [Member] | Adjupharm's CEO [Member]            
Disclosure of detailed information about business combination [line items]            
Percentage of shares granted     5.00%      
Amount of shares granted     $ 63      
Percentage of restricted shares granted     4.98%      
Percentage of restricted shares vest on March 1, 2020     2.50%      
Percentage of restricted shares vest on March 1, 2021     2.48%